Phase 1 Obesity Trial, Recruiting NCT07511205 Sponsor: AstraZeneca Condition: Obesity
Back to Obesity

Phase 1 Obesity Trial, Recruiting

NCT07511205
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Female participants must have a negative pregnancy test at the screening visit and at the time of admission to the clinic.
  • Female participants who cannot become pregnant must be confirmed as postmenopausal, or have records showing they have had a hysterectomy, removal of both ovaries, or removal of both fallopian tubes.
  • Body mass index (a measure of weight relative to height) must fall within a certain range — between 25 and 39.9 for the general (Global) groups, or between 23 and 39.9 for the Japanese and Chinese groups — and participants must weigh at least 50 kg.
  • For the Japanese groups (Parts A2 and B2), participants must be of Japanese heritage, with both parents and all four grandparents being Japanese, including second- and third-generation individuals of Japanese descent whose family members live outside Japan.
  • For the Chinese group (Part A3), participants must be of Chinese heritage, with both parents and all four grandparents being ethnically Chinese, including second- and third-generation individuals whose family members live outside China.

Who may not be able to join:

  • People with a history of any significant disease or medical condition.
  • People with a history or current presence of stomach, bowel, liver, or kidney problems, or any condition that could affect how the body processes medications.
  • People who have had a significant illness, surgery, or injury within the four weeks before the first dose of the study treatment.
  • People with significant abnormalities in blood tests, urine tests, or vital signs (such as blood pressure or heart rate).
  • People with a history of severe allergic reactions, or an ongoing significant allergy, to medications in the same drug family as AZD1043.
  • People who have taken prescription, over-the-counter, or experimental weight loss medications within the three months before the screening visit.
  • People with a history of psychosis, bipolar disorder, or major depressive disorder within the past two years who are currently not in a stable condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
30 March 2026
Est. completion
9 April 2027

Where this trial is recruiting

🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov